We right now believe we have plenty of supply to cover us through the end of the year and that's when we anticipate that DOXIL should be coming back online, according to announcements from Janssen or J&J.We also point out that we've been working closely with Janssen on this supply purchase and they've recognized the importance of the PROCEED trial and will work with us to help us make sure we get as much stock that's available. Second thing is the EU filing update. We continue to have good interactions and frequent interactions with the EU regulators. We have the vintafolide filing, which is EC145, ready to go. We had some discussion recently with the EU where they have asked us to put all the filings in at one time. We were going to do them sequential but they have requested that they come in all at one time, both the imaging and the therapeutic filing. And so we'll probably have all of those go in in the fourth quarter. It's not going to delay the review period at all. It's just a request by the EU to see – so that they don't have them come in one time period and one in the other. So we're anticipating the filing will happen this year and we'll have all applications go in at one time. Ig uses another comment on Merck, we've been very happy with the interactions of Merck so far. There has been a lot of work in preparation for the EU filing as well as potential commercialization in EU. We've been transitioning the manufacturing responsibilities for – of ertarfolatide or the EC145 to Merck. We're working with them on the new indications that they will be running besides the ovarian and lung study. And we're appreciating, I guess, the immediate commercial horsepower of Merck as we work through launch plans and start to enhance KOL relationships. And so really – and also they have been spectacular as a partner to work with.
These things often have some tough starts as you go along but they have just been outstanding to work with on all fronts.Of course, we've also announced that we've named David Meek as our Commercial Head. He's key to the interaction with Merck. We interviewed a number of candidates. We couldn't be happier with landing David. He is kind of the ideal person for this position. He has significant oncology experience. He's spent the last three or four years in Europe with Novartis and so he'll have great insight into the first launch, which will be in the EU. He's had multiple global marketing and senior leadership sales positions and he was just very – I mean, we're very lucky to get someone of his caliber to come to Endocyte. We look forward to introducing him to – in the future of calls. The other just update, I guess, is we've already announced, we've added a couple new board members to the board, Pete Meldrum and Marc Kozin. This is consistent with our plan to continue to build the right capabilities on the board as we transition from development into commercial phase of the company and accelerate our pipeline. So those are the updates and key milestones. I'll let Mike go over the financials and then we'll take questions. Mike Sherman Thanks, Ron. This is the first quarter, of course, in which we'll recognize the accounting for the Merck collaboration, so I want to make sure we spend some time covering how that will show up on our financial statement. And more importantly I think you'll see how that collaboration really puts us in a very strong position from a financial standpoint. Read the rest of this transcript for free on seekingalpha.com